Equities

LungLife AI Inc

LungLife AI Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)8.50
  • Today's Change0.00 / 0.00%
  • Shares traded1.18k
  • 1 Year change-90.00%
  • Beta-0.5286
Data delayed at least 20 minutes, as of Nov 11 2024 11:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year LungLife AI Inc grew revenues 91.67% from 24.00k to 46.00k while net income improved from a loss of 7.61m to a smaller loss of 5.41m.
Gross margin100.00%
Net profit margin-15,403.45%
Operating margin-15,941.38%
Return on assets-42.18%
Return on equity-48.59%
Return on investment-47.78%
More ▼

Cash flow in USDView more

In 2023, cash reserves at LungLife AI Inc fell by 364.00k. However, Cash Flow from Investing totalled 4.95m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.02m for operations while cash used for financing totalled 296.00k.
Cash flow per share-0.1214
Price/Cash flow per share--
Book value per share0.2419
Tangible book value per share0.0645
More ▼

Balance sheet in USDView more

LungLife AI Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio2.83
Quick ratio--
Total debt/total equity0.0266
Total debt/total capital0.0259
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.